RZLT 最新10-Q变化

相对上期新增的文字 · 来源:10-Q · 2026-05-12

• We are a late-stage rare disease company focused on developing therapies that substantially improve the quality of life for individuals living with hyperinsulinism (“HI”) by alleviating the burden of severe and debilitating hypoglycemia.

• Our priorities for the second half of 2026 are to: (i) achieve alignment with the U.S. Food and Drug Administration (“FDA”) on the path forward in congenital HI following the completion of the sunRIZE study and (ii) complete enrollment and announce topline data for the registrational Phase 3 upLIFT …

• On December 11, 2025, we announced that the sunRIZE study did not meet its primary (hypoglycemia events) or key secondary (time in hypoglycemia) endpoints. Although statistical significance for the secondary endpoint (% time in hypoglycemia by continuous glucose monitoring [“CGM”]) was not achieved …

• While we believe the pronounced placebo/study effect confounded the results, with a particular impact on the primary endpoint of hypoglycemia events by self-monitored blood glucose (“SMBG”) due to accompanying measurement bias, the totality of the data further supports previous clinical evidence tha…

• sunRIZE topline data as well as pre-specified and post-hoc data updates were shared by oral presentation at the Pediatric Endocrine Society Annual Meeting held on May 1, 2026, including CGM-based outcomes that demonstrated significant and consistent improvements in glycemic control in ersodetug trea…

相对上期删除的文字 · 来源:10-Q · 2026-02-12

• We are a late-stage rare disease company focused on developing biologics that significantly improve the quality of life for patients and their families.

• Our priorities for 2026 are to progress our two Phase 3 programs in congenital and tumor hyperinsulinism (“HI”). Our goals include (i) achieve alignment with the U.S. Food and Drug Administration (“FDA”) on the path forward in congenital HI, (ii) complete enrollment in the registrational tumor HI st…

• On December 11, 2025, we announced that the sunRIZE study did not meet its primary (hypoglycemia events) or key secondary (time in hypoglycemia) endpoints. The study demonstrated reductions from baseline in events and time in hypoglycemia in both treatment groups, but not enough to be statistically …

• While additional analyses are ongoing, initial observations from sunRIZE inform our belief that the pharmacologic response demonstrates therapeutic activity, which may be obscured by the nature of patient-monitored hypoglycemia endpoint, and hypoglycemia-avoidant confounding behaviors. The magnitude…

• In light of these limitations, assessing the potential benefit in the ongoing open-label extension (“OLE”) portion of the study will be important, including blood glucose levels in the placebo group following roll-over to ersodetug. All 59 participants who completed the study elected to continue to …

相对上期新增的文字 · 来源:10-Q · 2026-05-12

• Modifications to the upLIFT trial may fail to produce effective results.

• In an effort to align with FDA guidance and improve the likelihood of demonstrating efficacy, the FDA allowed us to modify the upLIFT trial design. Such modifications include, without limitation to, removing the need to conduct a randomized, double-blind, placebo-controlled trial with hypoglycemia e…

• The FDA may reject the additional datasets we are preparing in support of the sunRIZE trial.

• The FDA has expressed a willingness to accept additional datasets as it assesses the results of the sunRIZE trial to chart a path forward. The FDA encouraged us to submit study reports and analysis datasets from sunRIZE for the agency’s independent evaluation. However, there can be no guarantees tha…

相对上期删除的文字 · 来源:10-Q · 2026-02-12

• The development of ersodetug could be halted or significantly delayed for various reasons

• Ersodetug is vulnerable to the risks of failure inherent in the drug development process. Our sunRIZE trial failed to meet its primary and secondary endpoints, and we may not be able to obtain regulatory approval for commercialization. We will be meeting with the FDA prior to the end of calendar Q1 …

• If our clinical trials fail to replicate positive results from earlier preclinical studies or clinical trials conducted by us or third parties, we may be unable to successfully develop, obtain regulatory approval for or commercialize our product candidates.

• Our preclinical studies or early clinical trials of our product candidates, whether conducted by us or third parties, may not necessarily be predictive of the results of later clinical trials that we conduct. For example, despite promising results in our early clinical trials of ersodetug, our sunRI…

• Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in late-stage clinical trials after achieving positive results in early-stage development, and we cannot be certain that we will not face further setbacks for any future product candidates. These set…